Microsoft healthcare executive Elena Bonfiglioli joins electroCore board

ROCKAWAY, N.J. - Elena Bonfiglioli, Microsoft’s Global Business Leader for Healthcare, Pharma Life Sciences, and International clinical applications’ solutions, has been appointed to electroCore Inc.’s (NASDAQ:ECOR) Board of Directors, effective September 2, 2025. The micro-cap bioelectronic medicine company, currently valued at $40.27 million, has shown strong revenue growth of 30% over the last twelve months despite challenging market conditions.

Bonfiglioli replaces Peter Cuneo, who is retiring from the board of the commercial-stage bioelectronic medicine and wellness company. According to InvestingPro analysis, while electroCore maintains a FAIR financial health score, the stock has experienced significant pressure, declining over 64% in the past six months. Get access to detailed analysis and 7 additional ProTips with an InvestingPro subscription.

With over two decades of experience in the health sector, Bonfiglioli currently oversees go-to-market strategies, commercial operations, and partnerships at Microsoft, enabling artificial intelligence transformation initiatives in healthcare organizations globally.

"I am excited about electroCore’s ability to address chronic pain and other challenges with a drug-free solution that is accessible for so many people," Bonfiglioli said.

Since 2023, she has served as a member of the Drug Information Association for Europe, Middle East & Africa Regional Advisory Council. She also serves on the boards of several startups in Europe and the Middle East and as an advisor for biopharma organizations.

Bonfiglioli was selected twice as one of the top 50 AI Innovators by Intelligent Health and was a founding member of the Holomedicine Association. She has also served as Vice Chair of the DIGITALEUROPE Executive Council for Healthcare since 2021.

"We continue to strengthen our corporate governance, and adding an accomplished executive like Elena is an important next step," said Dan Goldberger, CEO of electroCore.

The company’s main prescription products include gammaCore non-invasive vagus nerve stimulation and Quell neurostimulator, which treat chronic pain syndromes through non-invasive neuromodulation technology.

This information is based on a company press release.

In other recent news, Electrocore reported a 20% increase in revenue for the second quarter of 2025, reaching $7.4 million. Despite this revenue growth, the company experienced a net loss of $3.7 million, which translates to a loss of $0.44 per share. Electrocore projects a cash balance of approximately $10.5 million by the end of the year. In a separate development, the company announced the appointment of Kelly Benning as Senior Vice President of its Truvaga wellness division. Benning brings extensive experience in digital health and AI-enabled technologies to the role. Her previous positions include executive roles at LiveMetric, IBM Watson Health, and CipherHealth. These developments reflect ongoing changes and growth within the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.